LONDON, March 5, 2026 /PRNewswire/ — The “Exosome Diagnostic and Therapeutics Market – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032” report has been added to the Credence Research Inc. offering.The global Exosome Diagnostic and Therapeutics Market is projected to grow from USD 41.3 Million in 2025 to an estimated USD 401.70 Million by 2032, registering an exceptional CAGR of 31.10% during the forecast period. The market’s rapid expansion reflects growing demand for non-invasive diagnostic methods, rising adoption of precision medicine, and the increasing role of exosomes as promising carriers for targeted therapeutic delivery across oncology, neurology, and other disease areas.Scope & Segmentation – Exosome Diagnostic and Therapeutics MarketThe report provides a comprehensive analysis of the global Exosome Diagnostic and Therapeutics Market, covering revenue forecasts from 2025 to 2032. It evaluates market drivers, trends, challenges, opportunities, competitive landscape, and regional dynamics influencing the adoption of exosome-based technologies. The study examines advances in non-invasive diagnostics, liquid biopsy applications, drug delivery systems, isolation platforms, and translational research efforts supporting exosome-based innovation.The report further assesses the role of exosomes in disease detection, treatment monitoring, precision medicine, and therapeutic delivery. It also analyzes the growing integration of exosome technologies across oncology, cardiovascular care, dermatology, neurology, and other medical applications, while highlighting the impact of R&D investments and commercialization partnerships on market development.The exosome diagnostic and therapeutics market is segmented based on type, product & service, source, application, end user, and geography.
Regional Growth Reflects Expanding Research, Precision Medicine Adoption, and Healthcare Investment
Credence Research Inc,
Tower C-1105, S 25,
Akash Tower,
Vishal Nagar,
Pimple Nilakh, Haveli,
Pune – 411027, India
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.credenceresearch.com/Logo: https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpgSOURCE Credence Research Inc.
- By Type, the market includes Exosome Diagnostics and Exosome Therapeutics.
- By Product & Service, the market covers Instruments & Services and Kits & Reagents.
- By Source, the market includes Stem Cells, Blood & Blood Plasma, Urine, and Other Sources.
- By Application, the market includes Cancer, Dermatological Diseases, Musculoskeletal Disorders, Cardiovascular Diseases, and Other Applications.
- By End User, the market includes Hospitals and Clinics & Physician Settings.
- By Geography, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with country-level coverage for major markets including the U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, China, Japan, India, South Korea, Southeast Asia, Brazil, Argentina, GCC Countries, and South Africa.
- This report provides a detailed view of one of the fastest-evolving segments in advanced diagnostics and therapeutics, with the market projected to expand nearly tenfold by 2032.
- It helps decision-makers understand how liquid biopsies, personalized medicine, biomarker discovery, and exosome-enabled drug delivery are reshaping clinical diagnostics and treatment pathways.
- The study highlights regional growth opportunities across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, helping companies assess expansion potential in both mature and emerging healthcare ecosystems.
- For CXOs, investors, biotech innovators, and diagnostic developers, this report delivers actionable intelligence to guide R&D strategy, commercialization priorities, partnership development, and long-term market positioning.
- Industry Landscape and Value Chain Assessment
- Supply-Side Evaluation
- Demand-Side Evaluation
- Stakeholder Mapping
- Porter’s Five Forces Review
- PESTLE Environment Assessment
- Market Forecast and Future Direction
- Short-Term Forecast (0–2 Years)
- Mid-Term Forecast (3–5 Years)
- Long-Term Forecast (5–10 Years)
- Market Entry and Expansion Strategy
- Customer and End-User Analysis
- Customer Experience Comparison
- Growth Opportunity Assessment
- Channel and Distribution Review
- Pricing Movement Analysis
- Regulatory and Compliance Review
- Sustainability and ESG Assessment
- Risk and Disruption Analysis
- Investment Return and Cost Evaluation
Attribute | Details |
Market Size 2025 | USD 41.3 Million |
Market Size 2032 | USD 401.70 Million |
CAGR (2026–2032) | 31.10 % |
Forecast Period | 2026–2032 |
Base Year | 2025 |
Historical Period | 2020–2024 |
Segmentation Covered | Type, Product & Service, Source, Application, End User, Geography |
Key Regions | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Major Players | NanoSomix, Inc.; Capricor Therapeutics, Inc.; NX Pharmagen, Inc.; Sistemic Ltd; Thermo Fisher Scientific, Inc.; Malvern Instruments Ltd; Exiqon A/S; Exosome Diagnostic, Inc.; Aethlon Medical, Inc.; System Biosciences, Inc. |
- North America holds the largest share of the exosome diagnostic and therapeutics market, accounting for approximately 42% of global revenue. The region’s dominance is supported by strong investments in biotechnology, the presence of advanced research institutions, early adoption of innovative diagnostic technologies, and high demand for precision medicine solutions. The U.S. remains the principal growth engine, backed by extensive funding and a strong translational research ecosystem.
- Europe contributes around 27% of the global market and benefits from robust academic research, public support for personalized medicine, and growing use of liquid biopsy technologies. Countries such as Germany, the U.K., and France are central to regional market expansion, supported by research collaborations and increasing use of exosome-based technologies in oncology and rare disease applications.
- NanoSomix, Inc.
- Capricor Therapeutics, Inc.
- NX Pharmagen, Inc.
- Sistemic Ltd
- Thermo Fisher Scientific, Inc.
- Malvern Instruments Ltd
- Exiqon A/S
- Exosome Diagnostic, Inc.
- Aethlon Medical, Inc.
- System Biosciences, Inc.
- In September 2025, mdxhealth announced the closing of its acquisition of Bio-Techne’s Exosome Diagnostics (ExoDx) business, including the ExoDx Prostate (EPI) test, a CLIA-certified clinical laboratory, and related assets.
- In July 2024, AcouSort AB initiated two new collaborations in the cell therapy space, one with a U.S.-based company and another with a European company, both beginning with three-month leases of the AcouWash system.
Credence Research Inc,
Tower C-1105, S 25,
Akash Tower,
Vishal Nagar,
Pimple Nilakh, Haveli,
Pune – 411027, India
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.credenceresearch.com/Logo: https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpgSOURCE Credence Research Inc.

Source link













Leave a Reply